New CEO commentary: “Understanding Skin Cancer”

August 13, 2018
Language flag

On the company’s webpage, PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence, see Commentary, “Understanding skin cancer”.

Latest News

The HoloMonitor HoloLids are specially designed to eliminate image disturbances, caused by surface vibrations and condensation inside the cell culture vessel.

Interim Report 4 2024/25

This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
A red pin on a blue map.

Phase Holographic: Proposal to amend the Altium Distribution Agreement

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) announces that the Board of Directors has decided to call for an Extraordinary General Meeting to approve a proposed amendment of the distribution agreement with Altium SA (“Altium”), the Company’s global distributor and main shareholder.
A magnifying glass on a paper with blue charts.

Phase Holographic: Sales summary and profit warning for the fiscal year 2024/2025

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) today provides an update on the Company’s sales for the fiscal year 2024/2025. Based on the most recent developments and actual order volumes, total sales for the fiscal year are now expected to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.
See All News